develop
updat
guidanc
aros
novemb
inform
provid
public
health
agenc
canada
regard
earli
data
indic
mismatch
influenza
vaccin
compon
emerg
season
strain
creat
need
updat
recommend
use
antivir
drug
year
season
influenza
concept
approv
associ
medic
microbiolog
infecti
diseas
ammi
canada
first
draft
cowritten
author
hg
fya
uda
gae
ml
subsequ
author
review
revis
approv
document
review
ammi
canada
guidelin
committe
infecti
diseas
immun
committe
canadian
paediatr
societi
ammi
canada
approv
final
document
submiss
journal
public
clinic
trial
neuraminidas
inhibitor
ni
oseltamivir
zanamivir
metaanalys
oseltamivir
therapi
administ
within
h
h
symptom
onset
lowrisk
outpati
influenza
placebocontrol
trial
ethic
safe
shown
overal
agent
shorten
durat
symptom
day
systemat
review
studi
investig
efficaci
ni
treat
mild
moder
influenza
ill
outpati
adequ
address
significantli
greater
benefit
ni
treatment
ill
hospit
patient
greater
benefit
earlier
treatment
onset
symptom
earlier
therapi
oral
oseltamivir
administ
within
h
symptom
onset
shown
reduc
symptom
day
inhal
zanamivir
shorten
durat
major
influenza
symptom
day
compar
placebo
individu
febril
enrol
receiv
zanamivir
within
h
lowrisk
outpati
ni
treatment
mild
influenza
ill
may
consid
option
hand
observ
cohortcontrol
studi
patient
sever
influenza
due
subtyp
pandem
subtyp
treat
hospit
oseltamivir
clearli
demonstr
reduct
mortal
benefit
still
observ
oseltamivir
start
day
onset
symptom
major
patient
usual
preexist
risk
factor
sever
influenza
approxim
healthi
younger
person
discern
risk
factor
current
influenza
season
influenza
account
major
influenza
case
document
test
addit
signific
antigen
drift
occur
major
influenza
strain
obtain
ill
patient
result
clinic
relev
mismatch
predomin
circul
influenza
viru
vaccin
strain
global
influenza
surveil
respons
system
laboratori
test
specimen
posit
influenza
virus
type
influenza
influenza
b
subtyp
influenza
virus
influenza
influenza
although
vaccin
may
still
provid
partial
protect
expect
optim
therefor
vaccin
individu
may
present
acut
care
facil
influenzalik
ill
ili
requir
treatment
ni
date
major
predomin
viru
isol
influenza
suscept
oseltamivir
zanamivir
isol
oseltamivir
zanamivirsuscept
almost
isol
influenza
b
also
suscept
oseltamivir
zanamivir
peak
influenza
activ
commun
case
definit
older
children
adult
fever
cough
posit
predict
valu
neg
predict
valu
influenza
patient
attend
outpati
clinic
cours
valu
vari
depend
preval
influenza
commun
rel
respiratori
infect
older
patient
chronic
obstruct
pulmonari
diseas
vaccin
influenza
presenc
fever
myalgia
correl
influenza
lower
posit
predict
valu
respiratori
virus
includ
limit
respiratori
syncyti
viru
rsv
adenoviru
parainfluenza
rhinoviru
coronaviru
human
metapneumoviru
infect
may
account
noninfluenza
infect
use
influenza
polymeras
chain
reaction
pcr
prefer
direct
fluoresc
antigen
detect
dfa
due
greater
sensit
nasopharyng
swab
prefer
influenza
pcr
test
particularli
patient
requir
hospit
admiss
patient
intub
endotrach
aspir
substitut
np
swab
np
swab
perform
neg
patient
subsequ
intub
endotrach
aspir
specimen
pcr
also
perform
multiplex
pcr
test
allow
diagnost
confirm
respiratori
virus
although
unlik
influenza
present
antivir
agent
avail
treat
treatment
patient
mild
ill
without
risk
factor
sever
complic
influenza
antivir
drug
recommend
h
pass
sinc
onset
influenzalik
symptom
howev
sever
ill
requir
hospit
oseltamivir
treatment
shown
reduc
mortal
even
treatment
start
h
start
symptom
follow
initi
clinic
assess
collect
appropri
specimen
viru
test
treatment
start
immedi
frequent
oseltamivir
oral
adult
normal
renal
function
typic
regimen
mg
everi
h
five
day
ventil
patient
oseltamivir
administ
nasogastr
tube
zanamivir
requir
sever
ill
patient
intraven
zanamivir
recommend
dose
mg
everi
h
intraven
zanamivir
need
obtain
request
govern
canada
health
protect
branch
special
access
program
ottawa
web
access
http
wwwhcsccahpbdgpstherapeut
telephon
weekday
hour
weekend
fax
inhal
zanamivir
advis
sever
ill
patient
inhal
powder
deposit
chiefli
upper
airway
zanamivir
powder
administ
ventil
circuit
contraind
recommend
dose
oral
oseltamivir
suspens
pediatr
patient
shown
tabl
dose
requir
patient
renal
impair
tabl
oseltamivir
oral
suspens
may
also
use
adult
patient
swallow
capsul
oseltamivir
oral
suspens
avail
oseltamivir
capsul
may
open
mix
sweeten
liquid
regular
sugarfre
chocol
syrup
children
old
enough
safe
swallow
capsul
mg
mg
capsul
also
taken
outlin
tabl
patient
sever
immunodefici
ill
patient
ventil
may
improv
continu
shed
influenza
virus
prolong
period
even
five
day
antivir
therapi
circumst
repeat
endotrach
sampl
sent
viral
pcr
suscept
test
oseltamivir
resist
suspect
oseltamivir
resist
prompt
switch
intraven
zanamivir
result
antivir
suscept
test
avail
repeat
viral
test
perform
clinic
condit
fail
improv
detail
discuss
appropri
antibiot
manag
patient
suspect
bacteri
pneumonia
beyond
scope
document
howev
patient
present
acut
respiratori
infect
background
influenza
outbreak
chest
radiograph
demonstr
pulmonari
infiltr
primari
influenza
secondari
bacteri
pneumonia
possibl
primari
influenza
pneumonia
typic
present
sever
short
breath
occur
within
one
three
day
initi
symptom
onset
clinician
awar
present
biphas
ill
reappear
fever
deferves
typic
influenza
ill
might
repres
complic
secondari
bacteri
pneumonia
bacteri
pneumonia
strongli
suspect
typic
influenza
ill
resolv
usual
around
fifth
day
recurr
fever
product
cough
often
alway
purul
sputum
sever
ill
patient
appropri
antibiot
communityacquir
nurs
homeacquir
pneumonia
institut
immedi
well
ni
antivir
drug
treatment
pend
etiolog
diagnosi
influenza
outbreak
individu
ili
admit
emerg
depart
hospit
place
droplet
contact
precaut
pend
result
test
np
swab
medic
personnel
use
appropri
ppe
droplet
contact
precaut
prior
contact
person
ili
influenza
viru
transmit
larg
droplet
spread
cough
mucos
contact
contamin
surfac
fomit
whether
vaccin
unvaccin
health
care
worker
hcw
wear
mask
gown
glove
care
individu
ili
hcw
develop
ili
symptom
immedi
sent
home
work
told
remain
home
guidelin
institut
occup
health
servic
consult
determin
hcw
return
work
hcw
use
person
health
care
provid
care
addit
inform
secondari
case
influenza
famili
member
index
case
reduc
earli
institut
postexposur
prophylact
oseltamivir
zanamivir
hospit
patient
hcw
regardless
vaccin
statu
unprotect
close
contact
patient
ili
may
offer
either
oseltamivir
dose
mg
daili
zanamivir
inhal
two
puff
mg
daili
seven
oseltamivir
zanamivir
day
reduc
chanc
influenza
ill
especi
import
influenza
season
face
vaccin
mismatch
postexposur
prophylaxi
less
like
effect
start
h
exposur
highrisk
patient
use
postexposur
prophylaxi
even
h
may
justifi
hcw
lowrisk
hospit
patient
identifi
h
exposur
observ
earli
treatment
symptom
aris
prefer
strategi
close
observ
earli
treatment
recommend
individu
choos
receiv
postexposur
antivir
prophylaxi
preexposur
prophylaxi
either
oseltamivir
zanamivir
hospit
patient
staff
routin
recommend
recommend
differ
resid
staff
longterm
chronic
care
facil
preexposur
prophylaxi
patient
may
consid
specif
circumst
eg
highrisk
semiclos
hospit
unit
transplant
unit
least
one
laboratoryconfirm
case
occur
hospit
unit
end
unit
outbreak
gener
consid
new
case
ili
appear
day
onset
last
case
preexposur
prophylaxi
increas
risk
longterm
use
develop
resist
